Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of botanical extracts derived from **Curcuma longa** (turmeric; containing curcumin as the principal active constituent) and **Boswellia serrata** (Indian frankincense; containing boswellic acids, notably 3-O-acetyl-11-keto-β-boswellic acid [AKBA]). Both extracts are widely used in traditional and modern medicine, primarily for their **anti-inflammatory** and **analgesic** effects. The combination is researched mostly as an oral dietary supplement for the management of pain and inflammation in **osteoarthritis**, musculoskeletal conditions, spondylitis, and as an adjunct in other inflammatory disorders. Proposed mechanisms of action include: inhibition of cyclooxygenase (COX) and lipoxygenase (LOX) pathways, suppression of pro-inflammatory cytokines (e.g., IL-1, TNF-α, IL-6), antioxidant effects via activation of Nrf2-related pathways, and inhibition of leukotriene and prostaglandin synthesis. Clinical studies suggest the combination may have additive or synergistic benefits versus monotherapy, resulting in symptom relief and functional improvement in osteoarthritis and other inflammatory states[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on curcuma longa extract + boswellia serrata extract.